Inventor · disambiguated record
Stephen H. Leppla
Also filed as: LEPPLA STEPHEN · LEPPLA STEPHEN H
37 granted patents·8 pending applications·356 citations·filing 1993–2019
97Inventor score
Files withUS HEALTH25CHEN ZHAOCHUN3LEPPLA STEPHEN H3THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES2US GOV HEALTH & HUMAN SERV2
Top patents by PatentIndex Score
45 records- 0190US5677274AAnthrax toxin fusion proteins and related methodsUS HEALTH·Filed 1993·Granted Oct 14, 1997·119 cites·12 claims
- 0286US9580492B2Monoclonal antibodies that neutralize anthrax toxinsUS HEALTH·Filed 2015·Granted Feb 28, 2017·2 cites·9 claims
- 0385US6592872B1Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion proteinUS HEALTH·Filed 1997·Granted Jul 15, 2003·62 cites·10 claims
- 0485US5591631AAnthrax toxin fusion proteins, nucleic acid encoding sameUS HEALTH·Filed 1993·Granted Jan 7, 1997·77 cites·13 claims
- 0584US7261900B2Recombinant modified Bacillus anthracis protective antigen for use in vaccinesUS HEALTH·Filed 2003·Granted Aug 28, 2007·15 cites·13 claims
- 0682US8071100B2Monoclonal antibodies that neutralize anthrax toxinsCHEN ZHAOCHUN·Filed 2008·Granted Dec 6, 2011·1 cites·7 claims
- 0782US7097965B2Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion proteinUS HEALTH·Filed 2003·Granted Aug 29, 2006·11 cites·6 claims
- 0882US6893835B2Anthrax lethal factor is a MAPK kinase proteaseUS HEALTH·Filed 2002·Granted May 17, 2005·7 cites·9 claims
- 0981US8481048B2Methods for preparing immunogenic conjugatesSCHNEERSON RACHEL·Filed 2009·Granted Jul 9, 2013·2 cites·16 claims
- 1081US7947289B2Multimeric protein toxins to target cells having multiple identifying characteristicsUS HEALTH·Filed 2005·Granted May 24, 2011·6 cites·29 claims
- 1181US6911203B2Anthrax lethal factor is a MAPK kinase proteaseUS HEALTH·Filed 2002·Granted Jun 28, 2005·6 cites·10 claims
- 1279US8394387B1Recombinant modified Bacillus anthracis protective antigen for use in vaccinesLEPPLA STEPHEN H·Filed 2007·Granted Mar 12, 2013·2 cites·13 claims
- 1378US9309322B2Antibodies to tumor endothelial marker 8FRANKEL ARTHUR E·Filed 2011·Granted Apr 12, 2016·2 cites·6 claims
- 1477US8961975B2Monoclonal antibodies that neutralize anthrax toxinsUS HEALTH·Filed 2013·Granted Feb 24, 2015·1 cites·12 claims
- 1577US8044189B2Bacillus anthracis protective antigen nucleic acid sequencesUS HEALTH·Filed 2010·Granted Oct 25, 2011·1 cites·8 claims
- 1675US8574853B2Monoclonal antibodies that neutralize anthrax toxinsCHEN ZHAOCHUN·Filed 2011·Granted Nov 5, 2013·1 cites·6 claims
- 1773US8703150B2Methods of using Bacillus anthracis protective antigen sequences for vaccinationLEPPLA STEPHEN H·Filed 2011·Granted Apr 22, 2014·1 cites·10 claims
- 1873US8388933B2Multimeric protein toxins to target cells having multiple identifying characteristicsLEPPLA STEPHEN H·Filed 2011·Granted Mar 5, 2013·3 cites·18 claims
- 1972US9555064B2Protease-deficient Bacillus anthracisPOMERANTSEV ANDREI P·Filed 2012·Granted Jan 31, 2017·3 cites·8 claims
- 2070US7803386B2Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilliUS HEALTH·Filed 2004·Granted Sep 28, 2010·5 cites·42 claims
- 2169US9730993B2Engineered anthrax lethal toxin for targeted deliveryTHE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES·Filed 2013·Granted Aug 15, 2017·2 cites·34 claims
- 2269US7763451B2Methods for preparing Bacillus anthracis protective antigen for use in vaccinesUS HEALTH·Filed 2002·Granted Jul 27, 2010·2 cites·30 claims
- 2369US7468352B1Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptorsUS HEALTH·Filed 2000·Granted Dec 23, 2008·3 cites·17 claims
- 2469US2015093412A1Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthraxUS HEALTH·Filed 2014·Application pending·0 cites
- 2568US7183071B2Anthrax lethal factor is a MAPK kinase proteaseUS HEALTH·Filed 2006·Granted Feb 27, 2007·1 cites·10 claims
- 2667US10053503B2Monoclonal antibodies that neutralize anthrax toxinsUS HEALTH·Filed 2017·Granted Aug 21, 2018·0 cites·8 claims
- 2767US7056693B2Anthrax lethal factor is a mapk kinase proteaseUS HEALTH·Filed 2005·Granted Jun 6, 2006·1 cites·6 claims
- 2866US2010330074A1Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthraxKUBLER-KIELB JOANNA·Filed 2009·Application pending·0 cites
- 2965US7625736B2Methods for preparing immunogenic conjugatesUS HEALTH·Filed 2004·Granted Dec 1, 2009·0 cites·14 claims
- 3065US6485925B1Anthrax lethal factor is a MAPK kinase proteaseUS HEALTH·Filed 1999·Granted Nov 26, 2002·20 cites·15 claims
- 3162US2019144527A1Monoclonal Antibodies that Neutralize Anthrax Protective Antigen (PA) ToxinTHE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2019·Application pending·0 cites
- 3261US10227395B2Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxinUS HEALTH·Filed 2014·Granted Mar 12, 2019·0 cites·9 claims
- 3361US8926986B2Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthraxUS HEALTH·Filed 2013·Granted Jan 6, 2015·0 cites·4 claims
- 3458US9403872B2Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptorsTHE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES·Filed 2014·Granted Aug 2, 2016·0 cites·5 claims
- 3558US8685396B2Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxinCHEN ZHAOCHUN·Filed 2005·Granted Apr 1, 2014·0 cites·14 claims
- 3655US10273548B2Protease-deficient bacillus anthracisUS HEALTH·Filed 2016·Granted Apr 30, 2019·0 cites·15 claims
- 3754US10273299B2Antibodies to tumor endothelial marker 8SCOTT & WHITE HEALTHCARE·Filed 2016·Granted Apr 30, 2019·0 cites·23 claims
- 3854US2002048590A1Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion proteinFiled 2001·Application pending·0 cites
- 3953US8791074B2Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptorsLEPPLA STEPHEN·Filed 2008·Granted Jul 29, 2014·0 cites·17 claims
- 4051US2006035813A1Methods and formulations comprising agonists and antagonists of nuclear hormone receptorsSTERNBERG ESTHER M·Filed 2003·Application pending·0 cites
- 4150US9890369B2Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factorUS HEALTH·Filed 2014·Granted Feb 13, 2018·0 cites·20 claims
- 4250US2008166375A1Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor CellsUS GOV HEALTH & HUMAN SERV·Filed 2004·Application pending·0 cites
- 4348US2010168012A1Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatutureGOVERNMENT OF THE US SECRETARY·Filed 2007·Application pending·0 cites
- 4447US2005123476A1Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteasesUS GOV HEALTH & HUMAN SERV·Filed 2002·Application pending·0 cites
- 4538US10835593B2Modified anthrax toxin protective antigenUS HEALTH·Filed 2016·Granted Nov 17, 2020·0 cites·5 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →